Marc Pharmaceuticals Announces Positive Pre-Clinical HIV Results; Will Begin Early Stage Studies of Betulinol Derivatives on Drug Resistant HIV Business Wire
click here to return to Business Wire main menu
DonateNow





Marc Pharmaceuticals Announces Positive Pre-Clinical HIV Results; Will Begin Early Stage Studies of Betulinol Derivatives on Drug Resistant HIV

Business Wire - August 4, 2005

STAMFORD, Conn.-- Preliminary experimental data from cellular tests conducted by university scientists working under a research grant sponsored by Marc Pharmaceuticals, Inc. (OTC:MPMA) (OTC:MPMAW) (OTC:MPMAZ) has demonstrated that a betulinol derivative inhibits HIV-1 replication by more than 90 percent with no evidence of detrimental changes to cell viability. These encouraging early stage results pave the way for further pre-clinical studies in drug resistant strains of HIV.

Betulinol is a naturally occurring compound that is isolated from the outer layer of the bark of the white birch tree. Betulinol derivatives are formed by replacing a specific atom or group of atoms within a betulinol molecule.

Although these results appear to suggest a new composition for inhibiting the HIV virus that causes AIDS, additional pre-clinical studies are needed to determine the potential of this new derivative. These early stage test results have not been proven in clinical trials and Marc Pharmaceuticals cannot predict whether this derivative will be useful for treating HIV infection or AIDS.

About Marc Pharmaceuticals:

Marc Pharmaceuticals is committed to identifying, developing and bringing to market, medicines and therapies that will elevate our quality of life and alleviate the suffering associated with debilitating and life threatening diseases. For more information, refer to the company Web site: www.marcpharmaceuticals.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

Statements in this release may relate to future events or Marc's future performance. Such statements are forward-looking statements that are subject to risks and uncertainties. Investors are cautioned that such forward-looking statements are subject to inherent risks that actual results may differ materially from such forward looking statements. Risks and uncertainties include but are not limited to, (a) Marc's products many not be proven to be safe or effective, (b) the FDA may not approve clinical trials for Marc's products, (c) Marc may depend substantially upon the efforts of contracting parties who may not perform adequately, (d) Marc's patent rights may not be sufficient to protect its products, (d) Marc may never earn a profit from its products, (e) Marc may not be able to raise the necessary funds that are needed for the continued research and development of its products, (f) Marc's licenses require substantial performance on its part to remain effective, including the payment of substantial sums, if Marc loses a license, it will lost the right to develop and market the drug which it covers, and (g) other groups may have developed similar inventions to those of Marc, and therefore Marc may be at a competitive disadvantage.

CONTACT: Marc Pharmaceuticals

Robert M. Cohen, 203-352-8817

rcohen@marcpharmaceuticals.com

or

Michael A. Burns & Associates

Virginia Stuart, 214-521-8596

vstuart@mbapr.com

SOURCE: Marc Pharmaceuticals


050804
BW050803

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .